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Summary
PIK3CA is mutated in diverse human cancers, but the functional effects of these mutations have not been defined. To
evaluate the consequences of PIK3CA alterations, the two most common mutations were inactivated by gene targeting
in colorectal cancer (CRC) cells. Biochemical analyses of these cells showed that mutant PIK3CA selectively regulated
the phosphorylation of AKT and the forkhead transcription factors FKHR and FKHRL1. PIK3CA mutations had little effect
on growth under standard conditions, but reduced cellular dependence on growth factors. PIK3CA mutations resulted in
attenuation of apoptosis and facilitated tumor invasion. Treatment with the PI3K inhibitor LY294002 abrogated PIK3CA
signaling and preferentially inhibited growth of PIK3CA mutant cells. These data have important implications for therapy
of cancers harboring PIK3CA alterations.S I G N I F I C A N C E
PI3K signaling pathways can be deregulated by a variety of mechanisms in human tumors. We have recently discovered that
mutations in PIK3CA, a key member of this pathway, occur in a significant fraction of colorectal, breast, brain, and other tumor
types. To evaluate the effect of PIK3CA mutation in human cancer cells, we selectively inactivated wild-type and mutant versions
of this gene in colorectal cancer cell lines and examined their phenotypes. Our analyses showed that PIK3CA plays an essential
role in tumor cell proliferation in adverse conditions as well as in invasion and metastasis. These results suggest that patients with
tumors containing PIK3CA mutations may ultimately benefit from therapy directed at mutant PIK3CA or its downstream targets.Introduction
PIK3CA encodes the p110α catalytic subunit of the class IA
phosphatidylinositol 3-kinases (PI3Ks). PI3Ks are heterodimers
composed of p110 catalytic and p85 regulatory subunits and
can be activated by recruitment to the cell surface by growth
factor receptor tyrosine kinases, such as the epidermal growth
factor receptor (EGFR) and the insulin receptor (Cantley, 2002;
Vanhaesebroeck and Waterfield, 1999). Active PI3Ks phospho-
rylate phosphatidylinositol 4,5-bisphosphate (PIP2) at the
3-position of the inositol ring, converting it to phosphatidyli-
nositol 3,4,5-triphosphate (PIP3). PIP3 acts as a docking site
for pleckstrin homology (PH)-containing proteins, such as the
AKT serine/threonine kinase, and for the 3-phosphoinositide-
dependent protein kinase-1 (PDK1) (Vanhaesebroeck and
Alessi, 2000). Once at the membrane, AKT is activated by
PDK1 and phosphorylates numerous protein targets, including
Tuberin (Manning et al., 2002), GSK3β (Cross et al., 1995), BAD
(Datta et al., 1997; del Peso et al., 1997), MDM2 (Mayo and
Donner, 2001; Zhou et al., 2001), p21 (WAF1/CIP1) (Lawlor and
Rotwein, 2000; Rossig et al., 2001), caspase 9 (Cardone et al.,
1998), IKK (Romashkova and Makarov, 1999), a subset of fork-
head transcription factors (Brunet et al., 1999; Guo et al., 1999;CANCER CELL : JUNE 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.Rena et al., 1999), and mTOR, which in turn regulates phos-
phorylation of p70-S6K and 4EBP1 (Harris and Lawrence,
2003; Nave et al., 1999). The biological consequences of AKT
activation are broad, and can be subdivided into regulation of
cell proliferation, survival, and motility (Katso et al., 2001; Vi-
vanco and Sawyers, 2002).
The PI3K pathway is genetically deregulated in human can-
cer at several levels. The tumor suppressor PTEN, which de-
phosphorylates PIP3 to PIP2, thus antagonizing PI3K activity,
is deleted or mutated in several different tumor types (Li et al.,
1997; Sansal and Sellers, 2004; Steck et al., 1997), and amplifi-
cation of genomic regions containing AKT or PIK3CA genes
has also been reported (Bellacosa et al., 1995; Cheng et al.,
1992; Cheng et al., 1996; Shayesteh et al., 1999). PIK3CA is
somatically mutated in over 25% of colorectal, gastric, breast,
and certain brain tumors (Samuels et al., 2004), and is mutated
at significant frequencies in other tumor types (Bachman et al.,
2004; Broderick et al., 2004; Campbell et al., 2004; Samuels et
al., 2004). From these mutation frequencies, PIK3CA appears
to be one of the most highly mutated oncogenes yet identified
in human cancers.
Interestingly, more than 80% of the mutations in PIK3CA
cluster in two small conserved regions within the helical andDOI 10.1016/j.ccr.2005.05.014 561
A R T I C L Ekinase domains (Samuels et al., 2004). The high frequency of
mutations in these hotspots is reminiscent of mutations found
in oncogenes such as KRAS and BRAF (Bos et al., 1987; Da-
vies et al., 2002; Rajagopalan et al., 2002), and is consistent
with the premise that alterations in PIK3CA are activating. In-
deed, hotspot mutations have previously been shown to en-
hance lipid kinase activity in vitro (Samuels et al., 2004; Kang
et al., 2005). Additionally, functional analyses of other members
of this pathway are consistent with an oncogenic role for
PIK3CA: heterozygous PTEN knockout mice show increased
tumor development (Di Cristofano et al., 1998; Podsypanina et
al., 1999; Suzuki et al., 1998), and overexpression of PIK3CA
as well as AKT genes has been shown to be transforming (Aoki
et al., 2000; Chang et al., 1997). However, the biochemical and
biologic effects of PIK3CA mutations have not been evaluated
in human cancer cells.
In this work, we have investigated the role of PIK3CA muta-
tion in human colorectal cancer (CRC) cells using a gene
targeting approach. Targeted homologous integration was
used to specifically disrupt either the mutant or wild-type allele
of PIK3CA in two colorectal cell lines, each harboring one of
the two major hotspot mutations. Because the parental and
targeted cells are identical except for the alteration at the
PIK3CA locus, they serve as a rigorously controlled system
with which to examine the effects of mutant PIK3CA alleles.
Our results indicate that both of the evaluated hotspot muta-
tions constitutively activate the AKT pathway, and that this ac-
tivation is essential for cellular growth under adverse condi-
tions in vitro, as well as for invasion.
Results
Gene targeting of PIK3CA in human cancer cells
To analyze the biologic and tumorigenic effects of PIK3CA, we
established isogenic cell lines in which either the wild-type or
mutant alleles of this gene were disrupted. The colorectal can-
cer cell lines HCT116 and DLD1 were selected for gene
targeting because each contains a different hotspot mutation
of PIK3CA: HCT116 has an H1047R alteration in exon 20 (ki-
nase domain), while DLD1 contains an E545K alteration in exon
9 (helical domain). In addition, both cell lines are diploid at the
PIK3CA locus and are susceptible to gene targeting through
homologous recombination (Shirasawa et al., 1993; Waldman
et al., 1995). The adeno-associated virus (AAV) targeting sys-
tem (Hirata et al., 2002; Kohli et al., 2004) was used to disrupt
exon 1 as depicted in Figure 1A, resulting in cells with an en-
dogenous functional allele and a nonfunctional targeted allele.
Clones in which the PIK3CA locus was appropriately targeted
were identified by polymerase chain reaction (PCR) using prim-
ers specific to the targeting vector and to adjacent genomic
sequences. The PIK3CA genotype of the clones was confirmed
by reverse transcription (RT)-PCR of the PIK3CA transcript
coupled with direct sequencing (Figure 1B). In all cases, clones
in which the mutant allele had been targeted expressed only
the wild-type allele, and vice versa (Figure 1B). Two clones of
each genotype were chosen from each cell line for in-depth
analysis, and both clones behaved similarly in all the studies
described below. Clones in which the mutant allele had been
disrupted and the wild-type allele was intact are referred to as
“wild-type” (WT) clones, while clones in which the wild-type562allele had been disrupted and the mutant allele was intact are
referred to as “mutant” clones.
As previous reports of PIK3CA targeting in the mouse re-
sulted in alterations of protein levels of the PI3K regulatory sub-
unit p85α (Bi et al., 1999), we examined whether PIK3CA
targeting in our clones might affect levels of other PI3K regula-
tory or catalytic subunits. Examination of protein levels of
p85α, p110β, p110γ, and p110δ showed similar protein levels
for all parental, mutant, and WT clones (Supplemental Figure S1).
The AKT pathway is activated in mutant
PIK3CA-containing clones
To examine the catalytic activity of mutant PIK3CA, we gener-
ated recombinant E545K and H1047R hotspot mutants and ex-
amined their lipid kinase activity in vitro. Both mutant proteins
showed increased PI3-kinase activity compared to wild-type
protein (Supplemental Figure S2), consistent with previous
studies showing that mutations in PIK3CA result in increased
lipid kinase activity (Samuels et al., 2004; Kang et al., 2005).
To determine the effects of mutant PIK3CA on signaling path-
ways, we first examined AKT phosphorylation, as such phos-
phorylation appears to be essential for PIK3CA signaling.
Levels of phosphorylated AKT in cells growing in normal
growth medium were determined using immunoblotting. We
found that mutant clones exhibited increased phosphorylation
of AKT in comparison to WT clones at residue Thr-308 as well
as Ser-473 (Figure 2A). To determine which of the three AKT
proteins, AKT1, AKT2, or AKT3, was affected by PIK3CA muta-
tion, each AKT protein was individually immunoprecipitated
and subjected to immunoblotting with the same phosphospec-
ific antibodies. These analyses showed that AKT1 is the pre-
dominant AKT isoform expressed in CRC and is activated in
cells with mutant PIK3CA (Figure 2B). To examine if the in-
creased activation of AKT was due to increased PIK3CA kinase
activity or increased stability of mutant protein, we evaluated
p110α protein levels and found that these were similar in all
WT and mutant clones (Supplemental Figure S1). These results
suggest that increased AKT phosphorylation is due to constitu-
tive activation of PIK3CA rather than alteration in its protein
levels.
AKT is known to directly phosphorylate a number of proteins
(Vivanco and Sawyers, 2002). To determine which AKT targets
are mediators of PI3K signaling in CRC cells, the phosphoryla-
tion of candidate targets was assessed using specific antibod-
ies. Increased phosphorylation of two forkhead transcription
factors of the FOXO family, FKHRL1 and FKHR, was detected
in the mutant clones (Figure 2C). Reduced levels of FKHR pro-
tein were observed in both mutant clones (Figure 2C), consis-
tent with a recent study suggesting that FKHR is regulated by
phosphorylation-dependent proteosome degradation (Aoki et
al., 2004). Surprisingly, analysis of other AKT downstream
targets, such as mTOR, 4E-BP1, p70-S6K, Tuberin, GSK3β,
and AFX showed no consistent differences in phosphorylation
among the WT and mutant clones (Supplemental Figure S3
and data not shown). Thus, in CRCs, mutant PIK3CA appears
to constitutively activate signaling through AKT1, and this sig-
nal appears to be propagated, at least in part, by its FKHR and
FKHRL1 substrates.CANCER CELL : JUNE 2005
A R T I C L EFigure 1. Disruption of the PIK3CA gene in human colorectal cancer cells
A: A portion of the PIK3CA locus is shown before and after targeting with the AAV targeting construct. A targeted insertion was made in exon 1 by
homologous recombination. p85BD, p85 binding domain; AAV-Neo-PIK3CA, the targeting construct; HA, homology arm; P, SV40 promoter; Neo, geneticin-
resistance gene; R-ITR, right inverted terminal repeat; L-ITR, left inverted terminal repeat; triangles, loxP sites; pA, polyadenylation signal. Three STOP codons
were added at the end of the Neo gene to ensure premature termination of the transcript.
B: The PIK3CA genotype of targeted DLD1 and HCT116 clones was determined by RT-PCR and sequencing of the PIK3CA transcript. The nucleotide and
amino acid alterations are indicated above the arrow. HCT116 cells contain a PIK3CA kinase domain mutation, while DLD1 cells contain a helical domain
mutation. Clones in which the mutant allele has been disrupted and the wild-type allele is intact are referred to as wild-type (WT) clones, while clones in
which the wild-type allele has been disrupted and mutant allele is intact are referred to as mutant (MUT) clones.PIK3CA mutation promotes growth factor-independent
cell proliferation
Mutations in oncogenes like PIK3CA presumably confer some
net growth advantage on the cancer cells in which they occur,
thereby facilitating clonal expansion. To assess the effects of
PIK3CA mutations on growth, we first investigated growth rate
on plastic tissue culture plates and in soft agar (Figures 3A–
3C). In the presence of media with 10% serum, all clones grew
similarly both on plastic and in soft agar. Consistent with this
result, no differences in growth of cells injected subcutane-
ously in athymic nude mice were observed among various
clones (Figure 3D). However, if the serum concentration was
reduced to 0.5%, wild-type clones grew at a lower rate than
mutant clones on plastic (Figure 3B). This difference was also
observed when the cells were assessed for anchorage inde-
pendence in 0.5% serum. Although all clones formed a similar
number of colonies in soft agar under reduced serum concen-
trations, WT clones formed smaller colonies than mutant
clones (Figure 3C).CANCER CELL : JUNE 2005To determine the biochemical basis for these growth dispari-
ties, we examined phosphorylation of the downstream media-
tors activated by PIK3CA. The most dramatic differences were
observed in AKT and its targets, FKHRL1 and FKHR. In 0.5%
serum, the level of phosphorylation of AKT and the two fork-
head proteins was much higher in the mutant clones than in
the WT clones, and was in fact as high as in the WT clones
grown in normal serum conditions (Figure 4A). In contrast,
other AKT targets such as GSK3β were not affected in this
manner in low serum concentrations (Supplemental Figure S4).
These results suggested that high serum concentration acti-
vates the pathway in the WT clones, and that mutant clones
are less sensitive to these factors because the pathway is al-
ready constitutively activated. To determine what serum factors
might be responsible for the activation observed in WT cells,
we tested the effects of various cellular growth factors. When
the cells were grown in 0.5% serum supplemented with either
EGF or insulin, the phosphorylation of FKHRL1 and FKHR in
WT clones was increased to levels similar to those observed in563
A R T I C L EFigure 2. Effects of PIK3CA mutation on AKT,
FKHRL1, and FKHR phosphorylation
A: Lysates from the indicated cells were im-
munoblotted with anti-phospho-AKT (Ser473),
anti-phospho-AKT (Thr308), and phosphoryla-
tion-independent anti-AKT (AKT). Cell lysates
contained similar amounts of total protein as
determined by immunoblotting with the anti-α-
tubulin antibody.
B: Lysates from mutant clone 1 (MUT) and WT
clone 1 (WT) were used for immunoprecipitation
with the indicated antibodies. Immunoprecipi-
tates were analyzed by Western blotting with an
anti-phospho-AKT antibody. The same blot was
stripped and reprobed with a pan-AKT anti-
body (bottom).
C: Lysates from the indicated clones were im-
munoblotted with anti-phospho-FKHRL1/phos-
pho-FKHR (Thr24/Thr32), anti-FKHR, anti-FKHRL1,
and anti-α-tubulin antibodies.mutant clones in the absence of EGF or insulin (Figure 4B).
Identical results were obtained when the cells were activated
with growth factors in the complete absence of serum (Supple-
mental Figure S5). In contrast, neither of these growth factors
had much effect on the constitutively activated proteins in the
mutant clones.
The decreased growth rate of the WT clones in reduced se-
rum could have arisen either through perturbations in cell cycle
progression (e.g., longer G1 phase) or through increased cell
death. To determine which mechanism was responsible, we as-
sessed cell cycle parameters via flow cytometry and apoptosis
via morphology. No differences in cell cycle parameters were
observed, regardless of the serum concentration in the growth
medium (data not shown). Similarly, when grown in 10% se-
rum, WT and mutant clones were indistinguishable with re-
spect to the level of apoptosis (<4% in all cases). However, in
reduced serum, there was a dramatic difference in apoptosis
between WT and mutant clones in both the HCT116 and DLD1
cell lines (Figure 5). These results are consistent with previous564results showing that AKT can function in an antiapoptotic man-
ner and that phosphorylation of FKHR and FKHRL1 by AKT
prevents their transcriptional activation of various proapoptotic
genes (Brunet et al., 1999; Modur et al., 2002; Nakamura et al.,
2000; Rokudai et al., 2002). To directly test whether inhibition
of FKHR would have the same effect on cellular survival as
PIK3CA mutation, we used siRNA to knock down FKHR protein
levels in HCT116 WT and mutant clones. We examined the ef-
fects of five different siRNA duplexes against FKHR: all showed
significant reduction of apoptosis of WT cells grown in 0.5%
serum, resulting in apoptosis levels similar to those observed
in mutant cells (Supplemental Figure S6). As expected, FKHR
knockdown in mutant cells had no effect on apoptosis levels
(Supplemental Figure S6). Taken together, these results suggest
that mutant PIK3CA is essential for growth factor-independent
cellular proliferation, and that this is achieved by AKT-mediated
resistance to apoptosis through inhibition of forkhead tran-
scription factors.CANCER CELL : JUNE 2005
A R T I C L EFigure 3. Effect of PIK3CA mutations on cell
growth
A and B: Cellular proliferation was assessed in
plastic culture plates using media containing
either 10% (A) or 0.5% (B) serum. Average cell
number at each time point was measured by
determining DNA content in ten replicate wells
using SYBR Green I.
C: Anchorage-independent proliferation of cell
clones was assessed by measuring colony
growth in soft agar in the presence of 0.5% se-
rum. Graphs indicate number of colonies
greater than 2 mm in diameter observed after
two weeks of growth.
D: Athymic nude mice were injected subcuta-
neously with the indicated clones and were ex-
amined for subcutaneous tumor growth two
weeks later.Mutant PIK3CA confers resistance
to TRAIL-induced apoptosis
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
is a member of the tumor necrosis factor family of ligands that
can initiate apoptosis by a pathway triggered by its interaction
with death receptors (Wang and El-Deiry, 2003). It has been
shown that T cells expressing TRAIL play a role in killing tumors
(Smyth et al., 2003), and previous data has indicated that acti-
vation of the AKT pathway can modulate this process in tumor
cells (Modur et al., 2002). To test the sensitivity of PIK3CA mu-
tant clones to TRAIL-induced apoptosis, time course studies
were performed in the presence of media with 10% serum.
Untreated cultures of WT and mutant PIK3CA clones contained
very few (0%–2%) apoptotic cells. Within 18 hr of exposure to
TRAIL, massive apoptosis occurred in the WT cells, while the
mutant cells were spared (Figure 6). In contrast to TRAIL, expo-
sure to the proapoptotic FAS ligand did not induce significant
apoptosis in either the WT or mutant clones (data not shown).
Mutant PIK3CA promotes cell migration and invasion
Previous experiments have shown that disruption of the PTEN
tumor suppressor gene increases the ability of the cells to mi-
grate (Tamura et al., 1998). Because PIK3CA activation and
PTEN disruption are predicted to have similar effects on accu-
mulation of PIP3, we evaluated migration and related pheno-
types of the PIK3CA clones. Boyden chamber assays showedCANCER CELL : JUNE 2005that HCT116 or DLD1 mutant clones had a 6- to 8-fold in-
creased ability to migrate through a porous membrane or to
invade through Matrigel (Figures 7A and 7B). To determine
whether these differences resulted in altered capacities for in-
vasive phenotypes in vivo, parental, WT, and mutant HCT116
clones were administered to athymic nude mice by tail vein
injection. Eight weeks after injection, mice with cells from par-
ental or mutant clones were obviously cachectic, while mice
receiving WT clones appeared healthy (Figure 7C). Accordingly,
the former mice had lost an average of w15% of their body
weight compared to the latter (Figure 7D) (p < 0.01, t test). At
necropsy, none of the mice injected with the WT clones had
tumors, while all but one of the mice that received parental or
mutant clones had tumors in various locations ranging in size
from 2 mm to 12 mm (Figure 7D) (difference between WT and
mutant clones was statistically significant, p < 0.001 by chi-
square test). Microscopic examination was performed on all
mice, and no additional tumors were found in the mice injected
with WT clones. However, numerous tumor micrometastases
and evidence of tumor invasion were observed in mice receiv-
ing mutant clones (Figure 7E).
Effects of LY294002 on wild-type and mutant PIK3CA
signaling and cell growth
LY294002 is a small molecule that competitively and reversibly
inhibits the ATP binding site of several different PI3Ks (Vlahos565
A R T I C L EFigure 4. PIK3CA mutation abrogates serum and
specific growth factor dependence of AKT,
FKHR, and FKHRL1 phosphorylation
A: Cells were grown in 10% or 0.5% serum, and
lysates prepared from them were immunoblot-
ted with the indicated antibodies.
B: Cells were grown in 0.5% serum for 19 hr and
then stimulated with epidermal growth factor
(EGF) or insulin (Ins). Similar results were ob-
tained for HCT116 cells (data not shown).the presence of LY294002. These predictions were verified bytion was greater for the mutant clones than it was for the WT
Figure 5. PIK3CA mutation confers resistance to apoptosis induced by growth factor depletion
Cells were grown in growth medium containing 0.5% serum for the indicated times. Apoptosis was assessed by fluorescence microscopy of Hoechst 33258-
stained cells.et al., 1994). To test whether LY294002 would inhibit mutant
forms of PIK3CA, cells were grown in 0.5% serum and treated
with 10 M LY294002 for two hours. In all cases, LY294002
inhibited AKT, FKHRL1, and FKHR phosphorylation in mutant
as well as WT clones (Figure 8A). The relative degree of inhibi-566clones. In fact, the level of phosphorylation of AKT, FKHR, and
FKHRL1 in the mutant clones following treatment with
LY294002 was reduced to that occurring in WT clones in the
absence of LY294002 treatment (Figure 8A). This result sug-
gested that WT clones would grow better than mutant cells inCANCER CELL : JUNE 2005
A R T I C L EFigure 6. Effect of PIK3CA mutation on TRAIL-induced apoptosis
Cells were grown on plastic in the presence of TRAIL, and apoptosis was assessed by fluorescence microscopy of Hoechst 33258-stained cells at the
indicated times.exposure of cells to LY294002, which resulted in reduced cell
proliferation to a greater extent in mutant cells than in WT cells
(Figures 8B and 8C). These results suggest that LY294002, de-
spite its limited specificity for PI3KCA (Davies et al., 2000; Fru-
man et al., 1998), preferentially inhibits mutant PIK3CA sig-
naling.
Discussion
The results reported above lead to several conclusions relevant
to the role of PIK3CA in colorectal neoplasia. First, the results
provide strong evidence that endogenous PIK3CA mutations
promote cellular phenotypes typical of neoplastic cells. Sec-
ond, the biochemical and biological effects of a mutation in the
helical domain, a region of unknown function, were identical to
those resulting from mutation in the catalytic kinase domain.
Third, the effects of PIK3CA mutations were generally more
discernable under unfavorable conditions than under conven-
tional in vitro conditions of growth. Fourth, PIK3CA mutations
conferred resistance to apoptosis, as evident upon growth in
reduced serum concentrations or after exposure to TRAIL.
Fifth, PIK3CA mutations conferred a dramatic ability to migrate
and invade in vitro as well as in vivo. And sixth, PIK3CA muta-
tions clearly activated one particular downstream pathway in-
volving AKT1, FKHR, and FKHRL1. These conclusions are dis-
cussed in more detail below.
Helical versus kinase domain mutations
One of the most remarkable observations made in this study
is that the two different mutations in PIK3CA conferred virtually
identical phenotypes, despite the fact that these phenotypes
were assessed in two unrelated CRC cell lines. Though the
mechanism through which kinase domain mutations exert their
effects are in principle clear (increased specific activity of the
enzyme), the mechanism(s) underlying the increased kinase ac-
tivity and enhanced pathway activation resulting from helical
domain mutations are not. It will be of interest to investigate
this issue further through structural studies of PIK3CA proteins
containing engineered mutations.
Selective growth conditions in vivo
Mutations in cancer genes must provide a growth advantage
in order for cells containing those mutations to become the
predominant clone within the population. In general, it is diffi-
cult to determine the environmental conditions that are respon-
sible for such growth selection in vivo. Our results provideCANCER CELL : JUNE 2005some clues as to what might have occurred during the devel-
opment of tumors with PIK3CA mutations in the human host.
Although there were relatively minor differences in growth be-
tween mutant and WT cells when cultured in conventional con-
ditions (10% serum), there were striking differences in growth
when cells were cultured in suboptimal conditions (0.5% se-
rum) (Figures 3–5). These differences in net growth rate were
accompanied by involvement of specific downstream media-
tors (e.g., AKT1 and forkhead proteins). The effects of serum
were mimicked by EGF or insulin, so that WT, but not mutant,
cells were dependent on these growth factors for pathway acti-
vation (Figure 4B and Supplemental Figure S5). These experi-
ments suggest a model where mutant PIK3CA tumor cells in
an environment with suboptimal growth factors, perhaps due
to inadequate vascularization, would be able to survive, and
perhaps even proliferate, while cells with WT PIK3CA would
die through apoptosis (Figure 5).
Migration, invasion, and metastasis
Though metastases are responsible for most cancer mortality,
the biochemical and genetic basis of this process is still being
investigated. Our results suggest that PIK3CA mutations not
only result in the capacity to migrate and invade in vitro, but
are also essential for forming metastases in a mouse model
when cells are intravenously injected (Figure 7). As invasion in
patients is initiated during the stage of tumorigenesis when
PIK3CA mutations generally occur (adenoma to carcinoma
transition [Samuels et al., 2004]), it is possible that PIK3CA is
one of the genes responsible for the invasive and metastatic
phenotypes in naturally occurring tumors. The hypothesis that
PIK3CA mutations contribute to invasion is consistent with pre-
vious studies indicating that PIK3CA and PTEN mutations oc-
cur late in glioma progression (Broderick et al., 2004; Wang et
al., 1997). Additionally, functional analyses have shown that
AKTs can regulate migration and invasive processes (Kim et
al., 2001; Park et al., 2001; Suzuki et al., 2004; Tamura et al.,
1998; Vasko et al., 2004), and that PTEN ablation enhances
migration and integrin-mediated cell spreading associated with
formation of focal adhesions (Tamura et al., 1998; Tamura et
al., 1999). Although the underlying mechanism for the invasive
phenotype is unclear, the striking differences between the WT
and mutant clones reported here should prove useful for evalu-
ating this issue in the future.
Downstream pathways
AKTs are hubs at the center of several major cell signaling
pathways, and AKT activation has been associated with a myr-567
A R T I C L Eiad of downstream mediators in different cell types and organ-
isms. Which of these downstream signaling molecules are ac-
tually responsible for transducing the mutant PIK3CA signal
can only be determined by examining pathway activation in
cells with those mutations. In the CRCs analyzed, AKT1 was
the predominant AKT isoform observed and found to be acti-
vated downstream of mutant PIK3CA (Figure 2B). This is con-
sistent with the fact that expression of AKT isoforms varies
among different tissues and cancer types (Altomare et al.,
1995; Nakatani et al., 1999) and that AKT1 has been reported
to be highly expressed in CRCs (Dufour et al., 2004). Our find-
ing that activation of AKT1 is involved in resistance to apopto-
sis in CRCs is consistent with data demonstrating AKT1 is
essential for cell survival (Dufour et al., 2004), that cells from
AKT1 knockout mice are susceptible to serum withdrawal in-
duced apoptosis (Chen et al., 2001), and that AKT1 is essentialFigure 7. Effect of PIK3CA mutation on tumor cell invasion in vitro and in vivo
A and B: Cells of the indicated genotypes were grown in Boyden chambers and assessed for their ability to migrate through porous 8 m membranes (A)
or invade through Matrigel (B). Each graph indicates the number of cells that migrated or invaded 24 hr after seeding.
C–E: Athymic nude mice were intravenously injected with cells from HCT116 parental, WT clones, or mutant clones and examined after eight weeks. C:
Severe cachexia was observed in mice injected with mutant or parental cells, whereas all mice containing WT cells appeared healthy. D: Mice injected
with mutant or parental cells developed tumors and lost weight, whereas none of the mice injected with WT cells had any pathologic abnormalities. E:
Representative hematoxylin and eosin-stained images of histopathological sections from mice injected with MUT1 clones: (i) numerous parenchymal
micrometases were present in the lung (arrows); (ii) a large tumor adjacent to the kidney (arrow); (iii) a tumor of the anterior mediastinum, which at a
higher magnification (iv) showed apparent distortion and invasion of the muscular layer surrounding a large pulmonary vessel.568for PTEN-controlled tumorigenesis (Stiles et al., 2002). Further
work will be required to evaluate AKT signaling mediated by
mutant PIK3CA in additional tumor types where other AKT iso-
forms may be highly expressed.
A surprising result was that only a selected subset of AKT
substrates was altered by PIK3CA mutation. Phosphorylation
of FKHRL1 and FKHR was dramatically affected, while the
phosphorylation of other substrates or mediators of AKT func-
tion was not consistently altered in mutant clones (i.e., ob-
served in all clones of both cell lines tested). Increased phos-
phorylation of FKHR has been shown to result in its
proteosomal degradation (Aoki et al., 2004), and phosphoryla-
tion of FKHR and FKHRL1 induces their exclusion from the
nucleus and their binding to 14-3-3 proteins in the cytoplasm
(Biggs et al., 1999; Brunet et al., 1999; Cahill et al., 2001; Kops
et al., 1999). Consistent with these reports, total FKHR proteinCANCER CELL : JUNE 2005
A R T I C L EFigure 8. Effect of the PI3K inhibitor LY294002 on PIK3CA signaling and cell
growth
For these analyses HCT116 and DLD1 WT clone 1 (WT) and mutant clone 1
(MUT) were examined.
A: Cells were grown in 0.5% serum and were treated with 10 M LY294002
diluted in DMSO or in DMSO alone for two hours or were left untreated. Cell
lysates were analyzed by immunoblotting using the indicated antibodies.
B: The effect of LY294002 on clonogenic growth was evaluated by treat-
ment of cells with 10 M LY294002 in 1% serum for two weeks. Results are
normalized to the number of colonies formed in control cultures treated
with DMSO alone.
C: The effect of LY294002 on cellular proliferation was assessed in plastic
culture plates. The average cell number at each time point was measured
by determining DNA content in four replicate wells using SYBR Green I after
treatment with either 5 M, 10 M, 20 M, or 50 M LY294002. Results are
normalized to cell growth treated with corresponding amounts of the
DMSO.CANCER CELL : JUNE 2005levels were reduced in mutant clones compared to WT clones
in the presence of serum, insulin, or EGF. These growth factors
increased the phosphorylation of FKHR and FKHRL1 in WT
clones, as expected, but their phosphorylation was constitu-
tively high in mutant clones, thereby allowing such cells to pro-
liferate under adverse conditions. The importance of this path-
way is bolstered by its evolutionary conservation. For example,
the C. elegans genome encodes a forkhead transcription fac-
tor, DAF-16, which is a downstream target of insulin/AKT
whose inactivation results in an increased life span (Lin et al.,
1997; Ogg et al., 1997). Our data also strengthen the evidence
that this pathway plays a critical role in neoplasia, first sug-
gested by the discovery of chromosomal translocations involv-
ing FKHR (Barr et al., 1993; Galili et al., 1993).
In addition to the forkhead transcription factors, other targets
of AKT have also been shown to be important for cell growth
and proliferation. For example, AKT-mediated inactivation of
GSK3β promotes cyclin D1 accumulation and cell cycle pro-
gression (Cross et al., 1995; Diehl et al., 1998). Additionally,
AKT phosphorylation of the protein kinase mTOR leads to
phosphorylation of p70-S6K, which enhances the translation
of specific mRNAs and inhibition of 4EBP1, a negative regula-
tor of translation (Harris and Lawrence, 2003; Nave et al.,
1999). Interestingly, the selective involvement of FKHR and
FKHRL1 observed in CRCs is different from the effects of over-
expression of mutant PIK3CA in chicken embryonic fibroblasts
(Kang et al., 2005) and the deletion of PTEN in mouse embry-
onic fibroblasts (Neshat et al., 2001), where other members of
the AKT pathway (including mTOR targets) appear to be af-
fected. Future work will be needed to determine if the targets
of AKT activation depend on the cell type, species, or experi-
mental system analyzed.
What happens downstream of FKHR and FKHRL1 phos-
phorylation in CRC cells with PIK3CA mutations is still un-
known. Our data suggest that PIK3CA mutations inhibit CRC
apoptosis under specific circumstances and promote tumor in-
vasion. Numerous mechanisms by which AKTs suppress apo-
ptosis or facilitate invasion have been suggested (Luo et al.,
2003; Majewski et al., 2004; Vivanco and Sawyers, 2002). The
observation that inhibition of FKHR resulted in apoptosis levels
similar to those of PIK3CA mutant cells (Supplemental Figure
S6) suggests that forkhead transcription factors play a major
role in bringing about these effects. Evaluation of transcripts
induced by FKHR and FKHRL1 in these cell lines through
microarray (Chee et al., 1996; Schena et al., 1995) or SAGE
technologies (Saha et al., 2002; Velculescu et al., 1995) should
therefore be particularly informative.
Finally, our results have potential therapeutic implications.
For one, they suggest that TRAIL, a TNF family member that
has been considered for clinical trials, is not likely to be very
useful in patients with PIK3CA mutations, and by extension, in
patients with AKT pathway activation caused by other muta-
tions. Second, the data in Figure 8 demonstrate that mutant
forms of PIK3CA can still be inhibited by broadly acting PI3K
inhibitors such as LY294002. This suggests that cells with
PIK3CA mutations are subject to “oncogenic addiction” and
that PI3K signaling is required for continued cell proliferation in
cancer cells (Kaelin, 1999; Lu et al., 2003; Neshat et al., 2001;
Sansal and Sellers, 2004; Weinstein, 2002). Interestingly, cells
deficient for PTEN have been shown to be more sensitive to
inhibitors of the PI3K pathway, and LY294002 has been shown569
A R T I C L Eto inhibit ovarian tumors with an activated PI3K pathway in
vivo (Hu et al., 2000; Neshat et al., 2001). One can imagine the
development of inhibitors that would specifically target one or
both of the two major mutant forms of PIK3CA (i.e., those in
the kinase and helical domains). As there are hundreds of thou-
sands of individuals each year who present with tumors con-
taining these specific PIK3CA mutations, this treatment ap-
proach could in theory be applicable to a large number of
patients.
Experimental procedures
Targeted deletion of the human PIK3CA locus
The approach for generating knockouts with AAV vectors was performed
as described (Hirata et al., 2002; Kohli et al., 2004). The targeting construct
pAAV-Neo-PIK3CA was constructed by PCR, using bacterial artificial chro-
mosome clone RPCI11.C (Invitrogen, Carlsbad, CA) as the template for the
homology arms. Constructs and primer sequences are available upon re-
quest. Stable G418-resistant clones were selected in the presence of either
0.4 mg/ml or 1 mg/ml for HCT116 and DLD1 cells, respectively (Invitrogen,
Carlsbad, CA), and were propagated in the absence of selective agents.
Genotypes of each clone were determined by RT-PCR and sequencing of
the coding region of PIK3CA.
Cell culture and reagents
The colon cancer cell lines HCT116 and DLD1 (ATCC, Manassas, Virginia)
were grown as described (Cummins et al., 2004a). Cell proliferation on plas-
tic was measured as described (Cummins et al., 2004b). For serum starva-
tion and growth factor stimulation, cells were grown to 70%–80% conflu-
ency, washed once with PBS, and incubated for 19 hr in McCoy’s 5A
modified medium containing 0.5% FCS. The cells were stimulated with 100
ng/ml insulin (Santa Cruz Biotechnology, Santa Cruz, CA) for 10 min or with
60 ng/ml EGF for 2.5 min (Cell Signaling, Beverly, MA). TRAIL treatment was
performed as described (Cummins et al., 2004a). LY294002 (Cell Signaling,
Beverly, MA) was applied at concentrations of 10 M.
Expression of p85α and p110α in Sf9 cells
Human recombinant PIK3R1, PIK3CA wild-type, and PIK3CA E545K and
H1047R mutants were expressed using the Invitrogen Bac-to-Bac Baculovi-
rus Expression System (Invitrogen, Carisbad, CA) (for detailed procedures,
see Supplemental Data).
Immunoblotting
Protein extracts from HCT116 and DLD1 clones were prepared by washing
the cells once in ice-cold phosphate-buffered saline and then lysing them
on ice in Laemelli sample buffer. The extracts were then briefly sonicated
and boiled, and debris was removed by centrifugation at 10,000 × g for 15
min at 4°C. Immunoblotting was performed with Immobilon P membranes
(MilliPore, Bedford, MA) (for details on antibodies used, see Supplemental
Data).
Immunoprecipitation
Immunoprecipitation was performed as described (Samuels et al., 2004) (for
detailed procedures and antibodies used, see Supplemental Data).
Focus formation assay in soft agar
HCT116 and DLD1 clones were plated in duplicate at 5000 cells/ml in top
plugs consisting of McCoy’s 5A modified medium containing various FCS
concentrations and 0.4% SeaPlaque agarose (FMC Bioproducts, Rockland,
Maine). After two weeks, the colonies were photographed, and the colonies
were digitally counted using Metamorph software. When all colony sizes
were considered, the total number of colonies formed by WT and mutant
clones was essentially the same. However, when colonies above the thresh-
old of 2 mm were counted, differences between the number of WT and
mutant clones were observed.
Cell cycle and apoptosis assays
Apoptosis assays were performed as described (Cummins et al., 2004a).
For analyses of cell cycle parameters, harvested cells were stained as for570apoptosis assays and evaluated by flow cytometry on a Beckman Coulter
EPICS XL according to the manufacturer’s instructions.
Knockdown of FKHR protein using siRNAs
siRNA analyses were performed using 27 bp RNA duplexes (Kim et al.,
2005). Five siRNA duplexes were used against FKHR: (1) 5#-CCAGGC
ATCTCATAACAAAATGATGAA-3#, (2) 5#-CCAGATGCCTATACAAACACTTC
AGGA-3#, (3) 5#-GGAGGTATGAGTCAGTATAACTGTGCG-3#, (4) GAGGTAT
GAGTCAGTATAACTGTGCGC, and (5) 5#-GGTCTGTCGCCCTTATCCTTCA
GCTCG-3# (IDT, Coralville, IA). A mixture of 4 siRNA duplexes (siControl)
each designed to haveR 4 mismatches to all human genes was used as a
control (Dharmacon Research Inc., Lafayette, CO). HCT116 WT and mutant
clones were cultured in 96-well plates until 60% confluent and were tran-
siently transfected with 1 nM siRNA duplexes using Lipofectamine 2000
(Invitrogen, Carisbad, CA). Both adherent cells and those in suspension
were collected and analyzed by immunoblotting and apoptosis assays.
Colony formation assay
Cell lines were plated at 1000 cells per T-25 flask in 1% serum concentra-
tion, and 48 hr later, medium containing 10 M LY294002 was added to
each flask. Plates were incubated for 14 days and stained with Hema3
(Sigma, St. Louis, MO).
In vitro migration and invasion assays and tumor
growth and invasion in mice
In vitro migration and invasion assays were performed using either 8 m
pore size transwell migration plates or Matrigel matrix-coated polycarbo-
nate filters, respectively (Biocoat, Beckton Dickinson, Bedford, MA). For tu-
mor growth assays, female athymic nude mice, obtained from Harlan (India-
napolis, IN) at 4 to 6 weeks of age, were injected subcutaneously in the
right foreleg with 5 × 106 HCT116 or DLD1 clones resuspended in 100 l of
PBS. Two weeks after injection, tumor size was measured. In vivo invasion
experiments were performed using 6- to 8-week-old female athymic nude
mice (Harlan, Indianapolis, IN), using tail vein injection of HCT116 clones.
For detailed procedures, see Supplemental Data. Animal protocols were
designed in accordance with the NIH Guide for the Care and Use of Labora-
tory Animals and were approved by the Johns Hopkins University Institu-
tional Animal Care and Use Committee.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/6/561/DC1/.
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